Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

After the screening procedures confirm that the participant is eligible to participate in the research study. The participant will be given a study drug-dosing calendar. The investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well they have tolerated their doses. Participants will receive the following: * Cytarabine * Microtransplantation * Lenalidomide